

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Brian Anderton, et al.
Serial No. : 10/562,951
Filing Date : December 23, 2005
Examiner : Not yet assigned
Group Art Unit : Not yet assigned
Entitled : "Screening Methods"

Suite 2400
1601 Market Street
Philadelphia, PA 19103
(215) 563-4100 (telephone)
(215) 563-4044 (facsimile)
Our File No. 0380-P03923US0

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97

Dear Sir:

In compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants are submitting herewith one sheet of Form PTO/SB/08a and four sheets of Form PTO/SB/08B listing references which the Examiner is respectfully requested to consider and make of record in this application. This Information Disclosure Statement is being filed more than three months after the filing date, but before receipt of the first Official Action on the merits. Thus, it is believed by the undersigned attorney that no fee is required under 37 C.F.R. §1.97(b).

Several references listed in this Information Disclosure Statement are from the International Search Report in the international application (PCT/GB/04/002739) on which this U.S. national stage patent application is based.

This submission is not an admission that the references listed on the attached Forms PTO/SB/08a and PTO/SB/08b constitute prior art against the claims of this application.

The above-identified international application entered the U.S. national phase after June 30, 2003. Therefore, copies of the U.S. patents and/or published U.S. applications listed on Forms PTO/SB/08a and PTO/SB/08b are not included (see O.G. Notice, August 5, 2003).


The Examiner is respectfully requested to confirm receipt and consideration of the cited references by initialing and returning a copy of the attached Forms PTO/SB/08a and PTO/SB/08b in accordance with MPEP §609.

In the event that any fee is required in connection with this submission and not enclosed, the Commissioner is authorized to charge such fee to the account of the undersigned attorneys, Account No. 04-1406. A duplicate copy of this paper is enclosed.

Early and favorable consideration of this application is respectfully requested.

Respectfully submitted,
DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation
Agent for Applicants

By:



Patrick J. Hagan
Registration No. 27,643

PJH:LCF

Enclosures - Forms PTO/SB/08a and PTO/SB/08b
- Copy of references

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
		Application Number	10/562,951
		Filing Date	December 23, 2005
		First Named Inventor	Brian Anderton, et al.
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
		Attorney Docket Number	0380-P03923US0
Sheet	1	of	2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/562,951
Filing Date	December 23, 2005
First Named Inventor	Brian Anderton, et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

Attorney Docket Number 0380-P03923US0

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

Application Number

10/562,951

Filing Date

December 23, 2005

First Named Inventor

Brian Anderton, et al.

Art Unit

Not yet assigned

Examiner Name

Not yet assigned

Attorney Docket Number

0380-P03923US0

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	MEIJER, L. et al., "Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent," Chemistry and Biology, 7:51-63, (2000)	
	C2	KURET, J. et al., "Casein Kinase 1 is Tightly Associated with Paired-Helical Filaments Isolated from Alzheimer's Disease Brain," J. of Neurochemistry, 69:2506-2515, (1997)	
	C3	SINGH, T. et al., "Phosphorylation of tau Protein by Casein Kinase-1 Converts it to an Abnormal Alzheimer-Like State," J. of Neurochemistry, 64:1420-1423, (1995)	
	C4	LEE G., et al., "Tyrosine Phosphorylation of Tau," Society for Neuroscience Abstracts, 27:1436, (2001)	
	C5	TROJANOWSKI, J., "Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases," Faseb J., 9:1570-1576, (1995)	
	C6	LARNER, A., "Tau protein as a therapeutic target in Alzheimer's disease and other neurodegenerative disorders," Expert Opinion on Therapeutic Patents, 9:1359-1370, (1999)	
	C7	CASTRO, A., et al., "Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of...," Expert Opinion on Therapeutic Patents, 10:1519-1527, (2000)	
	C8	SINGH, T., et al., "Non-proline-dependent protein kinases phosphorylate several sites found in tau from Alzheimer...," Molecular and Cellular Biochemistry, 154:143-151, (1996)	
	C9	RODER, H., "Prospect of Therapeutic Approaches to Tauopathies," J. of Molecular Neuroscience, 20:197-201, (2003)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.